Global Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Research Report 2024

Publication ID:

PB508247157

Publication Date:

August 29, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Multiparametric In-vitro Cardiotoxicity Testing refers to a set of laboratory-based techniques and assays used to evaluate the potential toxic effects of drugs, chemicals, or other substances on the cardiovascular system. It involves the assessment of multiple parameters or endpoints to comprehensively evaluate the cardiac safety profile of a substance.
The global Multiparametric In-vitro Cardiotoxicity Testing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
As the demands of drug development and chemical evaluation increase, the need for cardiotoxicity testing is also growing. Traditional animal testing methods have limitations such as high cost, long time, and ethical and moral issues, while Multiparametric in-vitro cardiotoxicity testing provides an alternative. By using cardiac cells, tissues or models, combined with multi-parameter measurements, it can more accurately evaluate the toxic effects of compounds on the heart, thereby improving the efficiency of drug safety assessment and chemical screening.
This report aims to provide a comprehensive presentation of the global market for Multiparametric In-vitro Cardiotoxicity Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiparametric In-vitro Cardiotoxicity Testing.
Report Scope
The Multiparametric In-vitro Cardiotoxicity Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiparametric In-vitro Cardiotoxicity Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiparametric In-vitro Cardiotoxicity Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Hemogenix
Molecular Devices
Creative Bioarray
FUJIFILM Cellular Dynamics
Agilent Technologies
Merck KGaA
Axol Bioscience
Miltenyi Biotec
Evotec
Enzo Life Sciences
Stemina Biomarker Discovery
Eurofins Discovery
Segment by Type
Calcium Transient Assay
Cardiac Marker Detection
Multi-ion Channel Assay
Others
Segment by Application
Contract Research Organizations (CROs)
Pharmaceutical and Biotech Companies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Multiparametric In-vitro Cardiotoxicity Testing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Calcium Transient Assay
1.2.3 Cardiac Marker Detection
1.2.4 Multi-ion Channel Assay
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Contract Research Organizations (CROs)
1.3.3 Pharmaceutical and Biotech Companies
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Perspective (2019-2030)
2.2 Multiparametric In-vitro Cardiotoxicity Testing Growth Trends by Region
2.2.1 Global Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Multiparametric In-vitro Cardiotoxicity Testing Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Multiparametric In-vitro Cardiotoxicity Testing Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Dynamics
2.3.1 Multiparametric In-vitro Cardiotoxicity Testing Industry Trends
2.3.2 Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Drivers
2.3.3 Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Challenges
2.3.4 Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Multiparametric In-vitro Cardiotoxicity Testing Players by Revenue
3.1.1 Global Top Multiparametric In-vitro Cardiotoxicity Testing Players by Revenue (2019-2024)
3.1.2 Global Multiparametric In-vitro Cardiotoxicity Testing Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Multiparametric In-vitro Cardiotoxicity Testing Revenue
3.4 Global Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Concentration Ratio
3.4.1 Global Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Multiparametric In-vitro Cardiotoxicity Testing Revenue in 2023
3.5 Multiparametric In-vitro Cardiotoxicity Testing Key Players Head office and Area Served
3.6 Key Players Multiparametric In-vitro Cardiotoxicity Testing Product Solution and Service
3.7 Date of Enter into Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Multiparametric In-vitro Cardiotoxicity Testing Breakdown Data by Type
4.1 Global Multiparametric In-vitro Cardiotoxicity Testing Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Multiparametric In-vitro Cardiotoxicity Testing Forecasted 麻豆原创 Size by Type (2025-2030)
5 Multiparametric In-vitro Cardiotoxicity Testing Breakdown Data by Application
5.1 Global Multiparametric In-vitro Cardiotoxicity Testing Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Multiparametric In-vitro Cardiotoxicity Testing Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size (2019-2030)
6.2 North America Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Country (2019-2024)
6.4 North America Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size (2019-2030)
7.2 Europe Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Country (2019-2024)
7.4 Europe Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size (2019-2030)
9.2 Latin America Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Multiparametric In-vitro Cardiotoxicity Testing 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Hemogenix
11.1.1 Hemogenix Company Detail
11.1.2 Hemogenix Business Overview
11.1.3 Hemogenix Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.1.4 Hemogenix Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.1.5 Hemogenix Recent Development
11.2 Molecular Devices
11.2.1 Molecular Devices Company Detail
11.2.2 Molecular Devices Business Overview
11.2.3 Molecular Devices Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.2.4 Molecular Devices Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.2.5 Molecular Devices Recent Development
11.3 Creative Bioarray
11.3.1 Creative Bioarray Company Detail
11.3.2 Creative Bioarray Business Overview
11.3.3 Creative Bioarray Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.3.4 Creative Bioarray Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.3.5 Creative Bioarray Recent Development
11.4 FUJIFILM Cellular Dynamics
11.4.1 FUJIFILM Cellular Dynamics Company Detail
11.4.2 FUJIFILM Cellular Dynamics Business Overview
11.4.3 FUJIFILM Cellular Dynamics Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.4.4 FUJIFILM Cellular Dynamics Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.4.5 FUJIFILM Cellular Dynamics Recent Development
11.5 Agilent Technologies
11.5.1 Agilent Technologies Company Detail
11.5.2 Agilent Technologies Business Overview
11.5.3 Agilent Technologies Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.5.4 Agilent Technologies Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.5.5 Agilent Technologies Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Detail
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.6.4 Merck KGaA Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.6.5 Merck KGaA Recent Development
11.7 Axol Bioscience
11.7.1 Axol Bioscience Company Detail
11.7.2 Axol Bioscience Business Overview
11.7.3 Axol Bioscience Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.7.4 Axol Bioscience Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.7.5 Axol Bioscience Recent Development
11.8 Miltenyi Biotec
11.8.1 Miltenyi Biotec Company Detail
11.8.2 Miltenyi Biotec Business Overview
11.8.3 Miltenyi Biotec Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.8.4 Miltenyi Biotec Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.8.5 Miltenyi Biotec Recent Development
11.9 Evotec
11.9.1 Evotec Company Detail
11.9.2 Evotec Business Overview
11.9.3 Evotec Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.9.4 Evotec Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.9.5 Evotec Recent Development
11.10 Enzo Life Sciences
11.10.1 Enzo Life Sciences Company Detail
11.10.2 Enzo Life Sciences Business Overview
11.10.3 Enzo Life Sciences Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.10.4 Enzo Life Sciences Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.10.5 Enzo Life Sciences Recent Development
11.11 Stemina Biomarker Discovery
11.11.1 Stemina Biomarker Discovery Company Detail
11.11.2 Stemina Biomarker Discovery Business Overview
11.11.3 Stemina Biomarker Discovery Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.11.4 Stemina Biomarker Discovery Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.11.5 Stemina Biomarker Discovery Recent Development
11.12 Eurofins Discovery
11.12.1 Eurofins Discovery Company Detail
11.12.2 Eurofins Discovery Business Overview
11.12.3 Eurofins Discovery Multiparametric In-vitro Cardiotoxicity Testing Introduction
11.12.4 Eurofins Discovery Revenue in Multiparametric In-vitro Cardiotoxicity Testing Business (2019-2024)
11.12.5 Eurofins Discovery Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Hemogenix
Molecular Devices
Creative Bioarray
FUJIFILM Cellular Dynamics
Agilent Technologies
Merck KGaA
Axol Bioscience
Miltenyi Biotec
Evotec
Enzo Life Sciences
Stemina Biomarker Discovery
Eurofins Discovery

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.